Caribou Biosciences Inc (CRBU)vsJohnson & Johnson (JNJ)
CRBU
Caribou Biosciences Inc
$1.88
-2.08%
HEALTHCARE · Cap: $205.84M
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 863436% more annual revenue ($96.36B vs $11.16M). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
CRBU
Avoid33
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.1%
Fair Value
$2.45
Current Price
$1.88
$0.57 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 89.7% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 89.7% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : CRBU
The primary concerns for CRBU are EPS Growth, Market Cap, Profit Margin.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CRBU profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.46 — expect wider price swings.
CRBU is growing revenue faster at 89.7% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 33/100), backed by strong 21.8% margins. CRBU offers better value entry with a 35.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology company leveraging advanced CRISPR technology to create transformative therapies for genetic disorders and oncology. With a robust pipeline of innovative product candidates, the company is dedicated to addressing significant unmet medical needs and enhancing the landscape of precision medicine. Caribou's strategic collaborations and focus on proprietary genome-editing solutions underscore its potential to redefine treatment approaches and deliver substantial benefits to patients, positioning it as a leader in the biopharmaceutical sector.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?